Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as age, obesity, type 2 diabetes, and endometriosis. As such, there are numerous avenues to help these patients successfully conceive, including pharmacologic agents such as clomiphene citrate and follicle-stimulating hormone (e.g., Merck KGaA’s Gonal F), as well as assisted reproductive technologies including in vitro fertilization. Thus, patient-specific considerations are often needed to determine the optimal plan for initiation of treatment. Pipeline agents (e.g., ObsEva’s nolasiban) are seeking to capitalize on unmet need for improving pregnancy rates, particularly for patients undergoing assisted reproductive technology-based procedures.
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
United States and EU5
Total, diagnosed, and drug-treated prevalent cases of female infertility by country, total prevalent cases by etiology, number of procedures due to female infertility
Drug-level sales and patient share of key female infertility therapies in 2027
Phase III/PR: 1 drugs. Phase II: 2 drugs. Coverage of select preclinical and Phase I products.